shutterstock_1349460623_pavel_kapysh

Pavel Kapysh / Shutterstock.com

1 March 2022Big PharmaMuireann Bolger

Ono sues AstraZeneca over antibody patents

Japan-based Ono Pharmaceuticals has sued AstraZeneca, accusing the US pharma company of infringing patents covering an antibody used in cancer treatment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More on this story

AstraZeneca, MSD sue MSN and Sandoz over Calquence generics

8 February 2022 AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.

Cancer centre sues BMS and Ono over alleged patent exploitation

25 June 2019 Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent